Global Therapeutic Protein Market 2021

January 2022 | 15 pages | ID: GEF363DE684EEN
StrategyHelix Inc

Abstracts

Therapeutic proteins are fast-acting and potent medicines and have proved very successful in the treatment of a wide range of indications. Therapeutic proteins are extensively used in the treatment of cancer, HIV, and other diseases. According to a report by StrategyHelix, the global therapeutic protein market is set to increase by US$ 138,375 million during 2021-2027, growing at a CAGR of 7.8% during the forecast period.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for therapeutic protein. The global therapeutic protein market is segmented on the basis of product, process, and region. On the basis of product, the global therapeutic protein market has been segmented into monoclonal antibodies, vaccines, peptide hormones, coagulation factors, cytokines, therapeutic enzymes, peptide antibiotics. The monoclonal antibodies segment is estimated to account for the largest share of the global therapeutic protein market. By process, the global therapeutic protein market has been segmented into cell culture, microbial fermentation, natural source, others. The cell culture segment held the largest revenue share in 2020. Geographically, the global therapeutic protein market is segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global therapeutic protein market is highly competitive. The prominent players operating in the global therapeutic protein market include AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, CSL Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Grifols S.A., Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Sanofi SA, Takeda Pharmaceutical Company Limited.

Report Scope
Product: monoclonal antibodies, vaccines, peptide hormones, coagulation factors, cytokines, therapeutic enzymes, peptide antibiotics
Process: cell culture, microbial fermentation, natural source, others
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global therapeutic protein market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. THERAPEUTIC PROTEIN MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY PRODUCT

Monoclonal antibodies
Vaccines
Peptide hormones
Coagulation factors
Cytokines
Therapeutic enzymes
Peptide antibiotics

PART 4. MARKET BREAKDOWN BY PROCESS

Cell culture
Microbial fermentation
Natural source
Others

PART 5. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 6. KEY COMPANIES

AbbVie Inc.
Alexion Pharmaceuticals, Inc.
Amgen Inc.
BioMarin Pharmaceutical Inc.
Bristol-Myers Squibb Company
CSL Limited
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Grifols, S.A.
Johnson & Johnson
Merck KGaA
Novartis AG
Novo Nordisk A/S
Pfizer Inc
Sanofi SA
Takeda Pharmaceutical Company Limited
About StrategyHelix
Disclaimer